Article Text

Download PDFPDF

POS0197 RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL
Free
  1. M. Boers1,
  2. P. G. Conaghan2,
  3. G. Schett3,
  4. P. Mandl4,
  5. E. Naredo5,
  6. F. Van den Bosch6,
  7. R. Burgos-Vargas7,
  8. A. M. Duggan8,
  9. P. Goyanka9,
  10. C. Gaillez10,
  11. M. A. D’agostino11
  1. 1Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
  2. 2University of Leeds, Rheumatology, Leeds, United Kingdom
  3. 3Friedrich Alexander University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3, Erlangen, Germany
  4. 4Medical University of Vienna, Division of Rheumatology, Vienna, Austria
  5. 5Hospital Fundación Jiménez Díaz and Autónoma University, Department of Rheumatology and Joint and Bone Research Unit, Madrid, Spain
  6. 6Ghent University and Ghent University Hospital, Rheumatology, Ghent, Belgium
  7. 7Hospital General de Mexico, Department of Rheumatology, Mexico City, Mexico
  8. 8Novartis Ireland Limited, Immunology, Hepatology and Dermatology, Dublin, Ireland
  9. 9Novartis Healthcare Private Limited, Immunology, Hepatology and Dermatology, Hyderabad, India
  10. 10Novartis Pharma AG, Immunology, Hepatology and Dermatology, Basel, Switzerland
  11. 11Catholic University of Sacred Heart, Rheumatology, Roma, Italy

Abstract

Background: Power Doppler ultrasonography is a sensitive imaging tool to assess synovitis in psoriatic arthritis (PsA).1,2 ULTIMATE (NCT02662985) is the first large, randomised, double-blind placebo-controlled phase IIIb study in PsA, using ultrasound to evaluate early response to secukinumab on synovitis. The use of the standardised and reliable global EULAR-OMERACT composite ultrasound synovitis score at patient level (GLOESS) as the primary endpoint showed the early and significant benefit of secukinumab vs. placebo on synovitis at week 12.3

Objectives: To investigate the responsiveness and discriminative validity of GLOESS compared to clinical outcomes on joints at week 12 and report ultrasound and clinical efficacy data up to week 24.

Methods: This is a 52-week study with a 12-week double-blind, placebo-controlled period followed by 12-week open-label (OL) and 6-month OL extension. All placebo patients were switched to secukinumab (300 or 150 mg) at week 12.3 Discriminative validity of GLOESS was analysed post-hoc: within-group responsiveness was assessed by comparing its standardised response mean (SRM) to that of core set of ACR response in the initial secukinumab group over 12 and 24 weeks. Mean change from baseline up to week 12 of GLOESS was determined with mixed-effect model repeated measures analysis (MMRM) and from week 12-24 as observed. 24 week efficacy outcomes included ACR responses, HAQ-DI, PASI response and resolution of dactylitis. These outcomes were exploratory and reported either according to non-responder imputation (ACR response), or as observed (HAQ-DI, PASI response and resolution of dactylitis).

Results: Of 166 patients enrolled, a total of 155 patients (93%) completed 24 weeks of treatment (secukinumab, 79 patients 95%; placebo, 76 patients 92%). Mean change from baseline to week 24 in GLOESS was similar in the initial secukinumab and placebo-secukinumab groups. A continued improvement in GLOESS was observed in the secukinumab group, with catch-up improvement in the placebo group after switch to active therapy (Figure 1). Both SRM of GLOESS and ACR core components over 12 and 24 weeks were high (Table 1). Similar clinical response rates were reported for clinical joint count, skin, dactylitis and function at week 24 in secukinumab and placebo switchers groups (Table 1).

Conclusion: These analyses highlight the responsiveness and high discriminative validity of GLOESS in PsA, resembling that of key clinical PsA manifestations and physical function.

References: [1]D’Agostino MA and Coates LC. J Rheumatol. 2019;46:337–9.

[2]Uson J, et al. Rheumatol Clin. 2018;14:27–35.

[3]D’Agostino MA, et al. Arthritis Rheumatol. 2020;72 (suppl 10).

Figure 1.

Mean change from baseline in GLOESS by treatment through Week 24

Table 1.

Responsiveness of GLOESS - analysed by standardised response mean and efficacy outcomes at week 24

Disclosure of Interests: Maarten Boers Consultant of: BMS, Novartis, Pfizer, GSK, Philip G Conaghan Speakers bureau: AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Consultant of: AbbVie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Peter Mandl Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, MSD, Novartis, Roche and UCB, Grant/research support from: AbbVie, BMS, Celgene, Janssen, Eli Lilly, MSD, Novartis, Roche and UCB, Esperanza Naredo Speakers bureau: AbbVie, Roche, BMS, Pfizer, UCB, Eli Lilly, Novartis, Janssen, and Celgene, Consultant of: AbbVie, Novartis and BMS, Grant/research support from: Eli Lilly, Filip van den Bosch Speakers bureau: AbbVie, Celgene, Janssen, Eli Lilly, Galapagos, Merck, Novartis, Pfizer, and UCB Pharma, Consultant of: AbbVie, Celgene, Janssen, Eli Lilly, Galapagos, Merck, Novartis, Pfizer, and UCB Pharma, Ruben Burgos-Vargas: None declared, Anne-Marie Duggan Employee of: Novartis, Punit Goyanka Employee of: Novartis, Corine Gaillez Shareholder of: Novartis and BMS, Employee of: Novartis, Maria-Antonietta D’Agostino Speakers bureau: Sanofi, Novartis, BMS, Janssen, Celgene, Roche, AbbVie, UCB, and Eli Lilly, Consultant of: Sanofi, Novartis, BMS, Janssen, Celgene, Roche, AbbVie, UCB, and Eli Lilly

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.